Loading
Cancer Related Molecular Pathways / Pi3k/akt/mtor Signaling in Cancer · Journal article
Journal of Ovarian Research · August 7, 2026
Raises a question worth testing. It does not answer one.
This is a mechanistic and preclinical study identifying RPPH1 as a regulator of c-Myc stability through CDK9 in ovarian cancer cell lines and xenografts. The work proposes CDK9 inhibition combined with cisplatin as a therapeutic strategy for RPPH1-overexpressing tumours, but lacks human clinical evidence and independent validation.
Bioinformatic screening, in vitro loss-of-function and gain-of-function studies, and mouse xenograft models. Ovarian cancer cell lines and xenograft tumour models; human samples analysed for RPPH1 expression and correlation with c-Myc activity and prognosis (cohort details not specified in abstract).. Intervention: RPPH1 loss-of-function and gain-of-function; CDK9 inhibitor Atuveciclib; combination of cisplatin and Atuveciclib in xenografts.. Compared with: Control (unstated); Atuveciclib alone versus combination with cisplatin in xenografts..
RPPH1 expression correlated with c-Myc activity and was upregulated in ovarian cancer. High RPPH1 levels predicted worse prognosis in the studied cohort. RPPH1 directly bound CDK9, promoting phosphorylation of c-Myc at Ser62 and prolonging its half-life.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The proposed RPPH1-CDK9-c-Myc axis and combination therapy strategy are mechanistic hypotheses that require validation in clinical trials before adoption in practice. The work may inform patient selection (RPPH1-high, cisplatin-resistant cases) for future studies of CDK9 inhibitors.
Mechanistic study in cell lines and xenografts identifying a regulatory pathway; no clinical trial data, and findings require confirmation in human subjects.
As stated by the source record.
The proposed RPPH1-CDK9-c-Myc axis and combination therapy strategy are mechanistic hypotheses that require validation in clinical trials before adoption in practice. The work may inform patient selection (RPPH1-high, cisplatin-resistant cases) for future studies of CDK9 inhibitors.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Dysregulation of the proto-oncogene c-Myc is a critical driver of ovarian cancer progression, yet the mechanisms governing its expression remain incompletely characterized. A systematic bioinformatic analysis was used to screen long non-coding RNA involved in the regulation of c-Myc transcriptional activity in ovarian cancer without MYC amplification. The functions of RPPH1 were investigated using loss-of-function and gain-of-function strategies in vitro and in vivo. The therapeutic potential of targeting this axis was evaluated using the CDK9 inhibitor Atuveciclib, alone and in combined with cisplatin, in ovarian cancer xenograft models. RPPH1 expression correlated with c-Myc activity was upregulated in ovarian cancer. High RPPH1 levels predicted worse prognosis. Mechanistically, RPPH1 directly bound CDK9, enhancing its stability and promoting phosphorylation of c-Myc at Ser62. This modification prolongs c-Myc’s half-life and amplifies its transcriptional activity. Atuveciclib abrogated RPPH1-driven c-Myc stabilization and activity, while combination therapy with cisplatin synergistically suppressed RPPH1-high tumour growth in xenograft models. We delineate a non-canonical RPPH1-CDK9-c-Myc axis governing oncoprotein stabilization in ovarian cancer, providing mechanistic insights into lncRNA-mediated post-translational regulation. CDK9 represents a therapeutic target for c-Myc-driven tumours, particularly RPPH1-overexpressing, cisplatin-resistant cases without MYC amplification. The combination of cisplatin and CDK9 inhibitor offers a promising translational strategy.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.